Janssen Reports the CHMP’s Positive Opinion of Balversa (Erdafitinib) to Treat Metastatic Urothelial Carcinoma (mUC)
Shots:
-
The CHMP has granted a positive opinion to Balversa monotx. (QD, oral) to treat inoperable mUC adults with susceptible FGFR3 mutations & previously treated with at least 1L of therapy with PD-1/PD-L1 inhibitor
-
The opinion was based on the arm 1 of P-III (THOR) trial assessing the safety & efficacy of erdafitinib (n=136) vs CT (n=130) for mUC. Trial was halted, in Jun 2023, at interim analysis with patients randomizing on CT & with an option of crossing over to erdafitinib
-
The study showed an mOS of 12.1mos. vs 7.8mos. at the data cut off, improved mPFS of 5.6mos. vs 2.7mos. and ORR of 35.3% vs 8.5%
Ref: Johnson & Johnson | Image: Johnson & Johnson
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
